NASDAQ:DCPH - Deciphera Pharmaceuticals Stock Price, Price Target & More

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals (NASDAQ:DCPH) issued its quarterly earnings data on Tuesday, May, 8th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.62) by $0.04. View Deciphera Pharmaceuticals' Earnings History.

6 Wall Street analysts have issued 1-year price objectives for Deciphera Pharmaceuticals' stock. Their predictions range from $30.00 to $57.00. On average, they anticipate Deciphera Pharmaceuticals' stock price to reach $43.3333 in the next year. View Analyst Ratings for Deciphera Pharmaceuticals.

Some companies that are related to Deciphera Pharmaceuticals include Array Biopharma (ARRY), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), TESARO (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO) and Arena Pharmaceuticals (ARNA).

(DCPH) raised $101 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals' lock-up period expired on Tuesday, March 27th. Deciphera Pharmaceuticals had issued 7,500,000 shares in its initial public offering on September 28th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. Shares of the company owned by company insiders and major shareholders are now eligible to be traded as a result of the end of the lock-up period.

News articles about DCPH stock have trended somewhat positive on Friday, according to Accern. Accern identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Deciphera Pharmaceuticals earned a coverage optimism score of 0.18 on Accern's scale. They also assigned news coverage about the company an impact score of 47.20 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Deciphera Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Redmile Group LLC (2.52%), BlackRock Inc. (1.53%), Opaleye Management Inc. (1.12%), Lord Abbett & CO. LLC (1.07%), JPMorgan Chase & Co. (0.88%) and Millennium Management LLC (0.74%). View Institutional Ownership Trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Sphera Funds Management LTD. and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Deciphera Pharmaceuticals.

DCPH stock was purchased by a variety of institutional investors in the last quarter, including Opaleye Management Inc., Redmile Group LLC, BlackRock Inc., JPMorgan Chase & Co., Eversept Partners LLC, Lord Abbett & CO. LLC, A.R.T. Advisors LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of DCPH stock can currently be purchased for approximately $25.31.

Deciphera Pharmaceuticals has a market capitalization of $842.56 million. The company earns $-50,280,000.00 in net income (profit) each year or ($2.99) on an earnings per share basis. Deciphera Pharmaceuticals employs 65 workers across the globe.

Deciphera Pharmaceuticals' mailing address is 500 Totten Pond Road, Waltham MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]